VLG Venture Life Group plc
Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers women's healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ name. It also provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos; and Glucogel for the treatment of hypoglycaemia. In addition, the company offers ENT care products comprising Earol, for the removal of ear wax; EarolSwim, an invisible ear plugs for protecting the ears from water ingress; and Baby Earol, an ear spray for babies under the Earol and EarolSwim brands. Further, it provides oncology support products, such as Pomi-T for the management of prostate-specific antigen levels in prostate cancer; and Gelclair, a muco-adhesive oral rinse for the treatment of Oral Mucositis. The company operates in Germany, the Netherlands, Norway, France, Sweden, Denmark, Lithuania, rest of Europe, the United States, Canada, Brazil, Ireland, and internationally. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.…
Industry Peers
Household & Personal ProductsKey Statistics
About Venture Life Group (LON: VLG)
›
Venture Life Group (LON: VLG) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Household & Personal Products industry, part of the Consumer Defensive sector, and reports about 63 employees.
The shares were at 68.50 GBp on 19 November 2026, up 16.1% over 52 weeks. Its 52-week range is 54.00 GBp to 72.00 GBp: the price is 4.9% below the high and 26.9% above the low.
Its market capitalisation is 81.42M GBP.
Venture Life Group reports an operating margin of 3.0% and revenue up 332.5% year over year.
It holds more cash than debt, a net cash position of 33.50M GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 150.00 GBp is 119.0% above the current price.